This message was sent to ##Email##
|
|
|
|
|
| |
The Institute of Cancer Research
Scientists have discovered a brand new way of attacking breast cancer that could lead to a new generation of drugs.
Researchers have revealed a new driver for the growth and spread of breast cancer cells and have designed a novel type of drug to block it.
The next step will be to select the most effective drug from this new class of inhibitors and take it into clinical trials of patients.
READ MORE
Medical Xpress
In the past, all forms of metastatic prostate cancer have been considered incurable. In recent years, the FDA has approved six drugs for men with metastatic disease, all of which can increase survival. In a study published in Urology, researchers demonstrate for the first time that an aggressive combination of systemic therapy (drug treatment) with local therapy (surgery and radiation) directed at both the primary tumor and metastasis can eliminate all detectable disease in selected patients with metastatic prostate cancer.
READ MORE
|
Promoted by
|
|
|
|
 |
The Annual Report to the Nation on the Status of Cancer 1975-2014 — a yearly collaboration between the National Cancer Institute, the American Cancer Society, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries — was published in the Journal of the National Cancer Institute on March 31, 2017.
Annual Report to the Nation on the Status of Cancer, 1975-2014
Key highlights include rates for new cancer cases, cancer deaths, and trends for the most common cancers in the United States, along with a special section on survival.
Annual Report to the Nation Materials to Share
All #ARN17 digital resources in one place. Download graphics and social media messages, and share them on Twitter, Facebook, Instagram and other social networks.
Annual Report to the Nation Press Release
Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups. Special section on survival finds significant improvement for all but two cancer sites.
Cure
A recent study found that survivors of Ewing sarcoma often face few long-term complications.
Ewing sarcoma is the second most common primary malignant bone tumor in childhood and adolescence, but thanks to developments in multimodal treatment, including systemic combination chemotherapy with surgery and/or radiotherapy for local control, survival rates have improved considerably over time — the current five-year overall survival rate for localized disease is 65 percent to 75 percent.
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
Enjoy our journals? There’s an app for those! Journals such as those from the American Cancer Society ™, Journal of Surgical Oncology, Cancer Science and more are now available for your iPad and iPhone. Sample issues and abstracts, as well as open articles, can be accessed for free. A subscription to the journal is required to read the full text. Click here to learn more!
|
|
Medical News Today
EGFR (Epidermal Growth Factor Receptors) are involved in the development and progression of many types of cancer and bowel cancer (colon carcinoma) in particular. So-called anti-EGFR antibodies are used in the treatment of bowel cancer patients to inhibit EGFR. However, for reasons that are not yet clear, not all patients benefit from this treatment. This could be due to the fact that EGFR is not only found in the tumor cells of bowel cancer patients but also in the immune cells surrounding the tumor. This was the main finding of a study conducted by a research team led by Maria Sibilia from MedUni Vienna's Institute of Cancer Research and recently published in leading journal Gastroenterology.
READ MORE
Medical Xpress
A new study by Yusheng Feng, professor of mechanical engineering at The University of Texas at San Antonio (UTSA), describes an algorithm that can predict the growth of cancerous tumors, which could help medical professionals judge the best treatment options for patients.
Feng first began researching cancer in 2002, predicting the outcomes of cancer treatments that utilize laser technology.
READ MORE
|
Promoted by
|
|
|
|
 |
CNBC
If you're a man between ages 55 to 69, one aspect of your medical care may have just gotten a little more confusing.
The U.S. Preventive Services Task Force, an independent and influential panel of experts, published new guidelines recently for screening for prostate cancer for the first time in five years. It changes a 2012 recommendation that one urologist described as "a public health nightmare."
READ MORE
OncLive
The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for May 24 to discuss a new drug application (NDA) for neratinib as a treatment for patients with HER2-positive breast cancer following prior treatment with postoperative trastuzumab (Herceptin), according to a statement from the developer of the TKI, Puma Biotechnology.
READ MORE
 |
|
Doctors Without Borders/Médecins Sans Frontières (MSF) is actively recruiting general and trauma surgeons with experience in emergency obstetrics for international missions in developing countries. Learn more.
|
|
ACS
As an American College of Surgeons (ACS) Quality Program participant, you contribute to the ACS mission of Inspiring Quality: Highest Standards, Better Outcomes. Your work, combined with that of the organization and its more than 80,000 ACS members, contributes to the continual improvement in care of the surgical patient.
Whether you are a physician, researcher, nurse or allied health professional, you help shape the care of surgical patients in a wide variety of health care, educational and office environments. That professional status makes you eligible for Affiliate membership.
READ MORE
Cure
The FDA has granted an accelerated approval to Tecentriq (atezolizumab) as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. The approval was announced by Genentech, the immunotherapy drug's manufacturer.
READ MORE
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The CoC and NAPBC do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons, the CoC and the NAPBC.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
